ID: ALA298950

Max Phase: Preclinical

Molecular Formula: C26H25N7O

Molecular Weight: 451.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCc1nc2c(C(N)=O)cccc2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1

Standard InChI:  InChI=1S/C26H25N7O/c1-2-3-11-23-28-24-21(25(27)34)9-6-10-22(24)33(23)16-17-12-14-18(15-13-17)19-7-4-5-8-20(19)26-29-31-32-30-26/h4-10,12-15H,2-3,11,16H2,1H3,(H2,27,34)(H,29,30,31,32)

Standard InChI Key:  KKTYSKIKXRYUFD-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 451.53

Molecular Weight (Monoisotopic): 451.2121

AlogP: 4.37

#Rotatable Bonds: 8

Polar Surface Area: 115.37

Molecular Species: ACID

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.85

CX Basic pKa: 4.68

CX LogP: 5.17

CX LogD: 4.11

Aromatic Rings: 5

Heavy Atoms: 34

QED Weighted: 0.36

Np Likeness Score: -1.04

References

1. Kubo K, Inada Y, Kohara Y, Sugiura Y, Ojima M, Itoh K, Furukawa Y, Nishikawa K, Naka T..  (1993)  Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles.,  36  (12): [PMID:8510105] [10.1021/jm00064a011]

2. Jain A, Chaturvedi SC.  (2010)  QSAR modeling of some substituted benzimidazole as Angotensin II AT1 receptor antagonist,  19  (2): [10.1007/s00044-009-9182-z]

Source

Source(1):

• Scientific Literature